GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (BSP:GILD34) » Definitions » E10

Gilead Sciences (BSP:GILD34) E10 : R$0.00 (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Gilead Sciences E10?

Note: As E10 is a main component used to calculate Shiller PE Ratio. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation sectione below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Gilead Sciences's adjusted earnings per share data for the three months ended in Mar. 2024 was R$0.000. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is R$0.00 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Gilead Sciences's average E10 Growth Rate was 6.80% per year. During the past 3 years, the average E10 Growth Rate was 9.50% per year. During the past 5 years, the average E10 Growth Rate was 6.70% per year. During the past 10 years, the average E10 Growth Rate was 16.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Gilead Sciences was 85.40% per year. The lowest was 4.50% per year. And the median was 31.65% per year.

As of today (2024-04-29), Gilead Sciences's current stock price is R$174.25. Gilead Sciences's E10 for the quarter that ended in Mar. 2024 was R$0.00. Gilead Sciences's Shiller PE Ratio of today is .

During the past 13 years, the highest Shiller PE Ratio of Gilead Sciences was 77.37. The lowest was 9.90. And the median was 14.99.


Gilead Sciences E10 Historical Data

The historical data trend for Gilead Sciences's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences E10 Chart

Gilead Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.54 12.67 16.02 15.96 15.71

Gilead Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.83 15.43 16.70 15.71 -

Competitive Comparison of Gilead Sciences's E10

For the Drug Manufacturers - General subindustry, Gilead Sciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gilead Sciences's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Gilead Sciences's Shiller PE Ratio falls into.



Gilead Sciences E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Gilead Sciences's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0/129.4194*129.4194
=0.000

Current CPI (Mar. 2024) = 129.4194.

Gilead Sciences Quarterly Data

per share eps CPI Adj_EPS
201406 2.460 100.560 3.166
201409 1.952 100.428 2.516
201412 2.880 99.070 3.762
201503 4.335 99.621 5.632
201506 4.543 100.684 5.840
201509 5.972 100.392 7.699
201512 6.170 99.792 8.002
201603 4.678 100.470 6.026
201606 4.416 101.688 5.620
201609 4.050 101.861 5.146
201612 3.924 101.863 4.986
201703 3.206 102.862 4.034
201706 3.839 103.349 4.807
201709 3.226 104.136 4.009
201712 -4.877 104.011 -6.068
201803 1.918 105.290 2.358
201806 2.621 106.317 3.191
201809 3.287 106.507 3.994
201812 0.004 105.998 0.005
201903 2.957 107.251 3.568
201906 2.834 108.070 3.394
201909 -1.895 108.329 -2.264
201912 4.351 108.420 5.194
202003 2.981 108.902 3.543
202006 -6.901 108.767 -8.211
202009 0.783 109.815 0.923
202012 3.164 109.897 3.726
202103 3.860 111.754 4.470
202106 3.042 114.631 3.434
202109 5.411 115.734 6.051
202112 0.848 117.630 0.933
202203 0.050 121.301 0.053
202206 2.297 125.017 2.378
202209 3.723 125.227 3.848
202212 3.410 125.222 3.524
202303 2.083 127.348 2.117
202306 2.014 128.729 2.025
202309 4.272 129.860 4.258
202312 2.793 129.419 2.793
202403 0.000 129.419 0.000

Add all the adjusted EPS together and divide 10 will get our e10.


Gilead Sciences  (BSP:GILD34) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

During the past 13 years, the highest Shiller P/E Ratio of Gilead Sciences was 77.37. The lowest was 9.90. And the median was 14.99.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Gilead Sciences E10 Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Gilead Sciences (BSP:GILD34) Business Description

Address
333 Lakeside Drive, Foster, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Gilead Sciences (BSP:GILD34) Headlines

No Headlines